#### Edgar Filing: KERYX BIOPHARMACEUTICALS INC - Form 3/A

#### KERYX BIOPHARMACEUTICALS INC

Form 3/A

August 06, 2010

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

**OMB APPROVAL** 

**OMB** Number:

3235-0104

Expires:

January 31, 2005

0.5

Estimated average burden hours per

response...

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF **SECURITIES** 

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*

FECZKO JOSEPH M

(Last)

C/O KERYX

Statement

(Month/Day/Year)

2. Date of Event Requiring 3. Issuer Name and Ticker or Trading Symbol

#### KERYX BIOPHARMACEUTICALS INC [KERX]

07/16/2010 (First) (Middle)

4. Relationship of Reporting Person(s) to Issuer

5. If Amendment, Date Original

Filing(Check Applicable Line) \_X\_ Form filed by One Reporting

Form filed by More than One

Filed(Month/Day/Year) 07/27/2010

(Check all applicable)

\_X\_ Director Officer

10% Owner Other 6. Individual or Joint/Group

(give title below) (specify below)

NEW YORK, NYÂ 10022

(Street)

(State)

BIOPHARMACEUTICALS, INC... 750 LEXINGTON

**AVENUE, 20TH FLOOR** 

Reporting Person Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security

(Instr. 4)

(City)

(Zip)

2. Amount of Securities Beneficially Owned

(Instr. 4)

Ownership Form:

4. Nature of Indirect Beneficial

Ownership (Instr. 5)

Person

Direct (D) or Indirect

(Instr. 5)

Common Stock (Restricted)

5,000 (1)

D

Â

Reminder: Report on a separate line for each class of securities beneficially

owned directly or indirectly.

SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)

2. Date Exercisable and **Expiration Date** (Month/Day/Year)

3. Title and Amount of Securities Underlying Derivative Security

Conversion or Exercise

Ownership Form of

6. Nature of Indirect Beneficial

Ownership

1

#### Edgar Filing: KERYX BIOPHARMACEUTICALS INC - Form 3/A

	Date Exercisable	Expiration Date	(Instr. 4) Title	Amount or Number of Shares	Price of Derivative Security	Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	(Instr. 5)
Stock Options (Right to Buy)	07/16/2011(2)	07/16/2020	Common Stock	50,000	\$ 3.7	D	Â

# **Reporting Owners**

Reporting Owner Name / Address	Relationships				
18	Director	10% Owner	Officer	Other	
FECZKO JOSEPH M					
C/O KERYX BIOPHARMACEUTICALS, INC.	â v	Â	â	â	
750 LEXINGTON AVENUE, 20TH FLOOR	АЛ	A	A	A	
NEW YORK, NY 10022					

## **Signatures**

/s/ James F. Oliviero, Attorney-in-fact

08/06/2010

\*\*Signature of Reporting Person

Date

### **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The shares of restricted stock vest as follows: 1/3 of each on July 16, 2011, July 16, 2012, and July 16, 2013.
- (2) The options vest as follows: 16,667 on July 16, 2011; 16,667 on July 16, 2012; and 16,666 on July 16, 2013.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 2